Collegium Pharmaceutical Stock News

Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares

Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report) today and set a price

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (NASDAQ:COLL) is set to announce its earnings results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of $0.32 per share for the

2 weeks Pain Therapeutics Conference - expert speakers

In a report released today, Serge Belanger from Needham maintained a Hold rating on Amphastar Pharmaceuticals (AMPH). The company's shares closed last

In a report released today, Serge Belanger from Needham maintained a Hold rating on Amphastar Pharmaceuticals ( AMPH – Research Report ). The company’s shares closed last Monday at $17.10. Accordi

Collegium Pharmaceutical Inc (NASDAQ:COLL) has received an average recommendation of “Buy” from the ten ratings firms that are currently covering the firm, MarketBeat reports. Four equities resear

Investment analysts at Needham & Company LLC started coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report issued to clients and investors on Friday, TipRanks reports. The

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Analysts at William Blair decreased their Q2 2020 earnings estimates for shares of Collegium Pharmaceutical in a research note issued to investors on Tue

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and Zogenix (ZGNX). Biogen (BIIB) In a report issued on

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen ( BIIB – Research Report ) and Zogenix ( ZGNX – Research Report ). Biogen (BIIB) In a report issued on Apri

Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares

Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report) today and set a price